Immuneering (IMRX) Operating Income (2020 - 2023)
Historic Operating Income for Immuneering (IMRX) over the last 4 years, with Q4 2023 value amounting to -$16.3 million.
- Immuneering's Operating Income fell 1656.76% to -$16.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$58.4 million, marking a year-over-year decrease of 1288.63%. This contributed to the annual value of -$58.4 million for FY2023, which is 1288.63% down from last year.
- As of Q4 2023, Immuneering's Operating Income stood at -$16.3 million, which was down 1656.76% from -$13.9 million recorded in Q3 2023.
- Immuneering's Operating Income's 5-year high stood at -$3.6 million during Q2 2020, with a 5-year trough of -$16.3 million in Q4 2023.
- Its 4-year average for Operating Income is -$10.5 million, with a median of -$11.6 million in 2022.
- Its Operating Income has fluctuated over the past 5 years, first plummeted by 12156.21% in 2021, then crashed by 559.74% in 2023.
- Over the past 4 years, Immuneering's Operating Income (Quarter) stood at -$5.8 million in 2020, then plummeted by 90.45% to -$11.1 million in 2021, then decreased by 25.81% to -$14.0 million in 2022, then dropped by 16.57% to -$16.3 million in 2023.
- Its Operating Income stands at -$16.3 million for Q4 2023, versus -$13.9 million for Q3 2023 and -$13.5 million for Q2 2023.